News | October 25, 2011

European Journal Features Results of Self-Apposing Stent Study


October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the September issue of the medical journal EuroIntervention.

The study showed the Stentys Self-Apposing Stent enabled the perfect apposition of these stents when treating patients with acute myocardial infarction (AMI). The self-apposing feature ensures optimal apposition during thrombus and vessel spasm relief in the critical initial hours and days after an AMI procedure; this avoids malapposition, a significant concern to cardiologists.

“We continue to be very pleased with the results of the Stentys Self-Apposing Stent when treating AMI,” said Giovanni Amoroso, M.D., OLVG Hospital (Amsterdam, the Netherlands) and lead author of the article. “During the six-month follow-up period of the APPOSITION I study, there was no death, no stent thrombosis or reoccurrence of MI, with revascularization rates comparable to that of conventional stents.”

EuroIntervention is the official publication of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI); it is endorsed by the European Society of Cardiology (ESC).

For more information: www.eurointervention.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now